The Cooper Companies, Inc. · NASDAQ:COO
The Cooper Companies — Investor Presentation (September 2021)
23 slides from The Cooper Companies's investor presentation, Sep 2, 2021
Slide 1: Investor Presentation
Investor Presentation September 2, 2021 1
Slide 2: Cautionary Statements
Cautionary Statements Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statement
Slide 3: A Leading Medical Device Company
A Leading Medical Device Company Improving lives one person at a time FY20 Revenue $2.43B 12,000+ Business Unit Geography Global Industry-leader Workforce in Vision and Women’s Health 10+ Women's Asia Pacific Health Manufacturing and Distribution Sites Member of the Americas S&P 500 since 100+ 2016
Slide 4: CooperCompanies: 6.2% annual sales growth 2015-2020
CooperCompanies 6.2% annual sales growth from 2015 to 2020 $2,533 $2,653 $2,431 $1,967 $2,139 $1,797 FY15 FY16 FY17 FY18 FY19 FY20 Note: Sales $ in millions; Annual sales growth is a five-year CAGR 4
Slide 5: Fiscal 2021 financial guidance
CooperCompanies Fiscal 2021 financial guidance FY21 Guidance* Growth vs. FY20 Total $2,893 - $2,923 16% - 18% cc Sales CooperVision $2,127 - $2,147 12% - 13% cc CooperSurgical $766 - $776 29% - 31% cc EPS Non-GAAP $13.20 - $13.40 37% - 39% asr Note: Sales $ in millions; cc means constant currency; a
Slide 6: CooperVision
CooperVision A global leader dedicated to helping improve the way people see each day 6
Slide 7: Global Soft Contact Lens Market
Global Soft Contact Lens Market High Barriers to Entry Market by Competitor Market by Category • High capital outlay with highly specialized manufacturing • Technological know-how Other CVI 12% Toric • Stringent FDA and worldwide regulation 25% 24% • Long history of product innovation (SiHy with int
Slide 8: The Growing Myopia Epidemic
The Growing Myopia Epidemic Myopia is expected to affect half the world population by 2050 Worldwide Prevalence of Myopia 4.7 billion 50% Why? Increased Less time screen time outdoors Genetics 2.6 billion 34% Myopia Significant Impact to Impaired 0.9 billion ocular quality of Risks learning and 22%
Slide 9: Contact Lens Market Drivers
Contact Lens Market Drivers Strong fundamental growth drivers • New fits/trade-up • Shift into 1 Day SiHy lenses • Growth in Torics and Multifocals New fits • Growing global wearer base Trade-up • Growing prevalence of myopia Geographic expansion • 1/3 of the world’s population is myopic going to 1/
Slide 10: A Global Leader in Myopia Management
A Global Leader in Myopia Management Broadest portfolio of science-based treatment options addressing the progression of myopia in children Ortho-k Only FDA approved Innovative myopia myopia control product management spectacles Broad range of market- leading Ortho-k lenses 10
Slide 11: MiSight 1 day
MiSight® 1 day First and only FDA-approved(1) myopia control contact lens • Clinically proven to slow the progression of myopia in children by up to 59%(2) • Launching Brilliant FuturesTM Myopia Management Program with MiSight® in multiple countries worldwide including the U.S. • Sold as a treatment
Slide 12: CooperVision: History of success
CooperVision History of success Durable Sales Growth Outpacing Market Growth Annual Sales Market Share CAGR 4.4% $1,973 25% $1,882 $1,843 24% 24% $1,488 $1,577 $1,674 23% 23% 22% FY15 FY16 FY17 FY18 FY19 FY20 CY15 CY16 CY17 CY18 CY19 CY20 Note: Sales $ in millions Source: Management estimates and in
Slide 13: Revenue by product category and geography
CooperVision Revenue by product category and geography FY20 Revenue $1.84B Revenue by Category Revenue by Geography Non single-use sphere, other Asia Pacific 28% 24% Single- use EMEA sphere Toric 37% 29% 32% Americas 39% Multifocal 11% 13
Slide 14: Well positioned to succeed
CooperVision Well positioned to succeed Products Support Relationships Diverse suite of best-in-class Branded and customized products to fit a wide range of Global footprint solutions patient needs Logistical and 1 Day FRP distribution excellence Strong key account Sphere Toric Multifocal relationsh
Slide 15: CooperSurgical: Healthy women, babies and families
CooperSurgical Healthy women, babies and familiesTM FY20 Revenue $588M Revenue by Category Fertility 39% Office & surgical products 61% 15
Slide 16: Global Fertility Market
Global Fertility Market Infertility in couples is high and growing Market Growth Drivers Up to 1 in 8 couples suffer from infertility worldwide • Increasing maternal age >$1B Global Market(1) • Greater access to treatment • Increased patient awareness and Annual comfort 5-10% Growth • Greater worldw
Slide 17: Fertility portfolio well positioned for success
CooperSurgical Fertility portfolio well positioned for success Medical Devices for the IVF Cycle(1) • Broadest medical device coverage of the entire IVF cycle(1) • Pioneers in IVF genetic testing • Market leading IVF tests developed inhouse in state-of-the-art R&D lab Note: (1) Medical devices for t
Slide 18: Intrauterine Contraceptive Devices (IUD) Market – U.S.
Intrauterine Contraceptive Devices (IUD) Market – U.S. Mid-single digit market growth Non- Hormonal 17% Increased awareness and desire for a non-hormonal product ~$1.2B 70% of women are concerned about hormones in birth control Hormonal 83% Opportunity to shift the U.S. market toward non-hormonal pr
Slide 19: CooperSurgical: Paragard IUD
CooperSurgical • Only US FDA-approved 100% Hormone Free IUD • Over 99% Effective • One simple active ingredient – Copper • Lasts up to 10 years with Immediate Reversibility • In office placement • Opportunity to create top of mind awareness Note: Paragard is included in CooperSurgical’s office and s
Slide 20: Office and surgical medical devices
CooperSurgical Office and surgical medical devices Gynecologists Obstetrics Office-based Labor & Operating providers Delivery room Opportunity and Drivers • Shift to minimally invasive procedures continues • Reimbursement is designed to drive procedures to the office • Health systems are looking for
Slide 21: CooperSurgical: History of success
CooperSurgical History of success Annual Sales CAGR 13.7% $651 $680 $588 $465 $390 $309 FY15 FY16 FY17 FY18 FY19 FY20 Note: Sales $ in millions 21
Slide 22: Socially and Environmentally Responsible
Socially and Environmentally Responsible Committed to enhancing the health and wellness of people and communities locally and globally Sustainability Our Employees Giving and Community Involvement 22
Slide 23: Well Positioned for the Future
Well Positioned for the Future Operating in two strong markets Revenue growth exceeding our markets Investing in the infrastructure of the business and new products Positioned to achieve long-term objectives Track record of success 23
The Cooper Companies — Investor Presentation (September 2021) on 6ix